Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.76 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.54 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.54 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31096355 | 1.00 | MAP2K1 (0.76) | MAP2K1MAP2K2MAP2K5PRKCZIARS2 | |
| SCHEMBL28645657 | 1.00 | MAP2K1 (0.76) | MAP2K1MAP2K2MAP2K5PRKCZIARS2 | |
| SCHEMBL31096371 | 1.00 | MAP2K1 (0.76) | MAP2K1MAP2K2MAP2K5PRKCZIARS2 | |
| SCHEMBL24407570 | 1.00 | MAP2K1 (0.76) | MAP2K1MAP2K2MAP2K5PRKCZIARS2 | |
| SCHEMBL24407608 | 0.91 | MAP2K1 (0.63) | MAP2K1MAP2K2MAP2K5PRKCZIARS2 | |
| SCHEMBL24407573 | 0.89 | MAP2K1 (0.60) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL24407522 | 0.89 | MAP2K1 (0.60) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL26047554 | 0.89 | MAP2K1 (0.60) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL26047576 | 0.85 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL31096306 | 0.83 | MAP2K1 (0.55) | MAP2K1MAP2K2PRKCZIARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220144819-A1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| CN-113660931-A | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113473986-A | Nalidinone aniline compounds for the treatment of skin disorders | 恩福莱克逊治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885MAP2K5 3568/4885 |
| US-20220144819-A1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, POLR1C, NQO1 | MAP2K1 461/4885MAP2K2 348/4885MAP2K5 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.